Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?
- PMID: 15319253
- DOI: 10.1093/annonc/mdh357
Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?
Comment on
-
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.Ann Oncol. 2004 Jan;15(1):100-3. doi: 10.1093/annonc/mdh025. Ann Oncol. 2004. PMID: 14679127 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources